Why I’m avoiding these 3 FTSE 100 stocks in 2020

G A Chester sees different issues with these three FTSE 100 (INDEXFTSE:UKX) stocks, but valuations are the acid test.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

There are a number of FTSE 100 stocks I think could disappoint investors in 2020. Among them are AstraZeneca (LSE: AZN), St. James’s Place (LSE: STJ) and Scottish Mortgage Investment Trust (LSE: SMT). Here’s why I’m avoiding these three.

Dubious core strength

AstraZeneca’s management has maintained the core earnings per share (EPS) guidance it gave at the start of the year of $3.50-$3.70 for 2019. At the midpoint and current exchange rates, this gives a price-to-earnings (P/E) ratio of 26.5 at a share price of 7,300p.

This is a huge premium to Footsie pharma peers GlaxoSmithKline and Hikma Pharmaceuticals, which trade at P/Es of 14.4 and 17.7 respectively. Furthermore, I’d argue AZN’s core EPS, on which the 26.5 P/E is based, grossly overstates its real core earnings, and that the true P/E is nearer a jaw-dropping 40.

This is because I exclude one-off profits from the divestment of non-core assets, which can’t go on forever but which AZN books as core operating profit. I also include legal costs (a routine expense in operating a big pharma company), which AZN excludes. AZN looks overvalued to me on its own core EPS measure, but grossly overvalued on what I consider its true core earnings.

Iffy business model

I’m avoiding wealth manager St. James’s Place on a view that it’s not only overvalued, but also has an iffy business model, and will have to change, with profit-margin-sapping consequences.

At a share price of around 1,100p, STJ’s P/E is 32.4 on forecast EPS of 34p for 2019. This earnings multiple is far too high, in my opinion. Furthermore, a valuation of more than 3% of funds under management (FUM) has proved a trusty indicator of overvaluation, in my experience. With a market capitalisation of £5.88bn, and FUM of £112.82bn, STJ is valued at 5.2% of FUM.

The company’s management fees and exit fees are excessive, in my view. Investors haven’t worried too much about this, seeing their portfolios increase in value over the last 10 years of rising markets, but are likely to pay a lot more attention in a downturn. Furthermore, with investors generally becoming a lot savvier about the corrosive effect of fees on returns, I think STJ will ultimately have to reset its margins.

Bonkers

It’s a peculiar and persistent feature of the UK stock market that some investment trust or another will rise from the FTSE 250 to the FTSE 100. However, no trust in history has gained sufficient critical mass to maintain its position in the top index.

Scottish Mortgage is the current representative in the FTSE 100. It’s achieved its status by a combination of high returns (471% over the last 10 years) and increasing popularity with investors (taking its shares to a premium to net asset value (NAV)).

The company has surfed on the outperformance of the US market and tech sector, holding a number of the so-called FAANG stocks, and the likes of Illumina and Tesla. The managers of the trust have borrowed money to gear returns (gearing is currently 9%), and remain optimistic on the outlook.

Personally, I think the valuations of many of the underlying holdings are bonkers. I fear a de-rating, SMT’s NAV dropping, gearing working negatively, and the shares moving to a wide discount to NAV. If so, SMT will become another in the long history of investment trusts failing to maintain a place in the FTSE 100.

G A Chester has no position in any of the shares mentioned. The Motley Fool UK owns shares of and has recommended GlaxoSmithKline and Tesla. The Motley Fool UK has recommended AstraZeneca and Hikma Pharmaceuticals. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Young Caucasian man making doubtful face at camera
Investing Articles

£20,000 in savings? Here’s how you can use that to target a £5,755 yearly second income

It might sound farfetched to turn £20k in savings into a £5k second income I can rely on come rain…

Read more »

Snowing on Jubilee Gardens in London at dusk
Investing Articles

Last-minute Christmas shopping? These shares look like good value…

Consumer spending has been weak in the US this year. But that might be creating opportunities for value investors looking…

Read more »

Dominos delivery man on skateboard holding pizza boxes
Investing Articles

2 passive income stocks offering dividend yields above 6%

While these UK dividend stocks have headed in very different directions this year, they're both now offering attractive yields.

Read more »

Black woman using smartphone at home, watching stock charts.
Investing Articles

How I’m aiming to outperform the S&P 500 with just 1 stock

A 25% head start means Stephen Wright feels good about his chances of beating the S&P 500 – at least,…

Read more »

British pound data
Investing Articles

Will the stock market crash in 2026? Here’s what 1 ‘expert’ thinks

Mark Hartley ponders the opinion of a popular market commentator who thinks the stock market might crash in 2026. Should…

Read more »

Investing Articles

Prediction: I think these FTSE 100 shares can outperform in 2026

All businesses go through challenges. But Stephen Wright thinks two FTSE 100 shares that have faltered in 2025 could outperform…

Read more »

pensive bearded business man sitting on chair looking out of the window
Dividend Shares

Prediction: 2026 will be the FTSE 100’s worst year since 2020

The FTSE 100 had a brilliant 2026, easily beating the US S&P 500 index. But after four years of good…

Read more »

Portrait of elderly man wearing white denim shirt and glasses looking up with hand on chin. Thoughtful senior entrepreneur, studio shot against grey background.
Dividend Shares

Prediction: the Lloyds share price could hit £1.25 in 2026

The Lloyds share price has had a splendid 2025 and is inching closer to the elusive £1 mark. But what…

Read more »